Development of vorinostat: current applications and future perspectives for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylase (HDAC) inhibitors, like vorinostat, modulate protein acetylation, a key post-translational modification.
• Protein acetylation influences critical cellular processes including cell growth, migration, and differentiation.
• Aberrant acetylation patterns are implicated in various cancers.

Purpose of the Study:

• To investigate the anti-cancer effects of vorinostat, a potent histone deacetylase inhibitor.
• To evaluate the impact of vorinostat on cellular acetylation patterns in transformed cells.
• To assess the clinical activity and tolerability of vorinostat in cancer patients.

Main Methods:

• In vitro and in vivo studies using transformed cell lines and animal tumor models.
• Administration of vorinostat at non-toxic concentrations for normal cells.
• Clinical trials assessing vorinostat efficacy and safety in patients with hematologic and solid tumors.

Main Results:

• Vorinostat induced significant alterations in cellular acetylation patterns.
• The drug caused growth arrest and cell death in a broad spectrum of transformed cells.
• Vorinostat demonstrated promising clinical activity and was well-tolerated in patients.

Conclusions:

• Vorinostat is an effective histone deacetylase inhibitor with potent anti-cancer activity.
• Its ability to modify acetylation patterns offers a promising therapeutic strategy for cancer treatment.
• Further clinical investigation, including combination therapies, is warranted.